JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Corvus Pharmaceuticals Inc

Fermé

7.16 -0.28

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.01

Max

7.35

Chiffres clés

By Trading Economics

Revenu

-23M

-8M

Marge bénéficiaire

-13,764.773

Employés

31

EBITDA

-360K

-10M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+94.99% upside

Dividendes

By Dow Jones

Prochains Résultats

12 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

224M

557M

Ouverture précédente

7.44

Clôture précédente

7.16

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 oct. 2025, 20:49 UTC

Résultats

Correction to Thermo Fisher Article on Oct. 22

23 oct. 2025, 23:51 UTC

Market Talk

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 oct. 2025, 23:49 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 oct. 2025, 23:37 UTC

Market Talk

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 oct. 2025, 22:58 UTC

Market Talk

Global Energy Roundup: Market Talk

23 oct. 2025, 22:57 UTC

Market Talk

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 oct. 2025, 22:49 UTC

Acquisitions, Fusions, Rachats

How Trump Sparked a New Era of State Capitalism -2-

23 oct. 2025, 22:49 UTC

Acquisitions, Fusions, Rachats

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 oct. 2025, 22:17 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 oct. 2025, 21:41 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 oct. 2025, 21:05 UTC

Résultats

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 oct. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

23 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 oct. 2025, 20:35 UTC

Résultats

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 oct. 2025, 20:28 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 oct. 2025, 20:15 UTC

Market Talk
Résultats

Global Commodities Roundup: Market Talk

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q Adj EPS $1.71

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q Sales $5.52B

23 oct. 2025, 20:10 UTC

Résultats

Newmont Mining 3Q EPS $1.67

23 oct. 2025, 20:09 UTC

Résultats

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 oct. 2025, 20:07 UTC

Market Talk
Résultats

Global Equities Roundup: Market Talk

23 oct. 2025, 20:07 UTC

Market Talk
Résultats

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 oct. 2025, 20:07 UTC

Résultats

Blackstone Looks to IPOs for Investment Exits -- Update

23 oct. 2025, 20:05 UTC

Résultats

Intel 3Q Gross Margin 38.2% >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 oct. 2025, 20:04 UTC

Résultats

Intel: 4Q Guidance Excludes Altera >INTC

23 oct. 2025, 20:04 UTC

Résultats

Intel Sees 4Q Adj EPS 8c >INTC

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

94.99% hausse

Prévisions sur 12 Mois

Moyen 14 USD  94.99%

Haut 16 USD

Bas 11 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

3 ratings

3

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

3.165 / 3.5827Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat